Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema
IOI developed in four of 56 (7.1%) eyes and responded well to prompt steroid therapy after 1.5 years of IVBr use for DME. BCVA and CMT improved at all evaluation time points. With an average of 3.8 IVBr injections per year, IVBr showed long-term efficacy for DME in the real-world setting, although the occurrence of IOI should be monitored.
Authors
- Yoshiaki Takahashi (ORCID: https://orcid.org/0000-0002-3034-693X)
- Shun Ito (ORCID: https://orcid.org/0000-0002-1387-3439)
- Ken Hoshiyama (ORCID: https://orcid.org/0000-0003-1314-7565)
- Takao Hirano (ORCID: https://orcid.org/0000-0003-3601-8053)
- Yoshiaki Chiku
- Toshinori Murata (ORCID: https://orcid.org/0000-0001-6577-5032)
Institutions
- Shinshu University (JP)
- Ome Municipal General Hospital (JP)
- Nagano Municipal Hospital (JP)
- Shinshu University Hospital (JP)
- Suwa Red Cross Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Ophthalmology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1007/s10384-025-01226-y
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Shinshu University
- Japan Society for the Promotion of Science